Navigation Links
A New Monoclonal Antibody Kills Cancer Cells

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.

Using a newly available monoclonal antibody, they demonstrated significant reductions in tumor cell proliferation and survival in human and mouse hepatocellular cancer (HCC) cell lines.

According to the researchers, this finding has significant implications not only for the treatment of liver cancer but for a number of different types of cancer.

Most cases of HCC are secondary to either a viral hepatitis infection or cirrhosis of the liver. Despite recent advances, it remains a disease of grim prognosis due to the poorly understood mechanism of how the disease originates and spreads. Most patients live only a short time after diagnosis.

Based on previous studies showing that some pathways that were previously thought to be active only during fetal liver development, particularly the class III receptor tyrosine kinase (RTK) family pathway, became highly active again in the liver of HCC patients, Satdarshan P. Singh Monga, M.D., associate professor, division of cellular and molecular pathology and colleagues at the University of Pittsburgh School of Medicine, obtained rat and human liver cancer cell lines and analyzed them for level of expression of an RTK protein known as platelet-derived growth factor receptor-alpha. The investigators also analyzed the cells for their level of activation of the PDGFR gene.

At an early fetal stage of liver development in the mouse, the investigators found that the level of expression of PDGFR was 37 times higher compared to later stages of development in the adult mouse liver.

They also found significantly higher levels of PDGFR in rat and human liver cancer cell lines as compared to normal cells in culture.

Dr. Mong as group then treated human and mouse liver cancer cell lines with a monoclonal antibody targeted against PDGFR alpha. It resulted in a significant decrease in tumor cell proliferation and a marked increase in tumor cell death.

In fact, all tumor cell lines experienced significant decreases in proliferation in response to the monoclonal antibody and there was a 4- to 18-fold increase in programmed cell death, or apoptosis, among the cancer cell lines compared to normal control cells.

According to Dr. Monga, these results suggest that PDGFR alpha offers an important new therapeutic target for the treatment of HCC.

We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work.

We now have identified a pathway that appears to be overly active in more than 70 percent of the cancers we examined and, when targeted, leads to significant reduction in tumor cell proliferation and survival, said Dr. Monga.

More importantly, targeting the PDGFR pathway in liver cancer cells does not appear to affect normal liver cells, making the treatment relatively non-toxic.

Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease, he added.

Furthermore, because high expression of PDGFR alpha has been detected in a variety of tumors, such as skin cancer, brain tumors, gastrointestinal tumors, prostate tumors, ovarian cancer and leukemia, Dr. Monga believes these findings could have much broader applications.


'"/>




Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
4. Monoclonal Antibody based system for Anthrax detection
5. Monoclonal Antibody Reduces Exacerbations in Asthmatics
6. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
7. Monoclonal Antibody Induces Death in Liver Cancer Cells
8. Human Antibody That Can Block SARS
9. Cuba Registers New Antibody
10. Single Sugar Enables Antibody to Treat Inflammation
11. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
Breaking Medicine Technology: